Crohn鈥檚 disease (CD) is an inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from mouth to the anus. It is caused by a combination of environmental, immune, and bacterial factors, in genetically predisposed individuals.
麻豆原创 Analysis and Insights: Global Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创
The global Crohn鈥檚 Disease Diagnostic and Therapeutic market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
This market is closely related to the pharmaceutical market.The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Crohn鈥檚 Disease Diagnostic and Therapeutic market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Crohn鈥檚 Disease Diagnostic and Therapeutic, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Crohn鈥檚 Disease Diagnostic and Therapeutic, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Crohn鈥檚 Disease Diagnostic and Therapeutic revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Crohn鈥檚 Disease Diagnostic and Therapeutic market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Crohn鈥檚 Disease Diagnostic and Therapeutic revenue, projected growth trends, production technology, application and end-user industry.
麻豆原创 Segmentation
By Company
Abbvie
Celgene
Genetech
Johnson & Johnson
Pfizer
Prometheus Laboratories
Salix Pharmaceuticals
Takeda Pharmaceutical
Segment by Type
Diagnostics
Treatment
Segment by Application
Hospital
Medical Research Institute
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Crohn鈥檚 Disease Diagnostic and Therapeutic in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Crohn鈥檚 Disease Diagnostic and Therapeutic companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Crohn鈥檚 Disease Diagnostic and Therapeutic revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Diagnostics
1.2.3 Treatment
1.3 麻豆原创 by Application
1.3.1 Global Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Medical Research Institute
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Perspective (2019-2030)
2.2 Global Crohn鈥檚 Disease Diagnostic and Therapeutic Growth Trends by Region
2.2.1 Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Crohn鈥檚 Disease Diagnostic and Therapeutic Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Crohn鈥檚 Disease Diagnostic and Therapeutic Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Dynamics
2.3.1 Crohn鈥檚 Disease Diagnostic and Therapeutic Industry Trends
2.3.2 Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Drivers
2.3.3 Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Challenges
2.3.4 Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Crohn鈥檚 Disease Diagnostic and Therapeutic by Players
3.1.1 Global Crohn鈥檚 Disease Diagnostic and Therapeutic Revenue by Players (2019-2024)
3.1.2 Global Crohn鈥檚 Disease Diagnostic and Therapeutic Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Crohn鈥檚 Disease Diagnostic and Therapeutic, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Concentration Ratio
3.4.1 Global Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Crohn鈥檚 Disease Diagnostic and Therapeutic Revenue in 2023
3.5 Global Key Players of Crohn鈥檚 Disease Diagnostic and Therapeutic Head office and Area Served
3.6 Global Key Players of Crohn鈥檚 Disease Diagnostic and Therapeutic, Product and Application
3.7 Global Key Players of Crohn鈥檚 Disease Diagnostic and Therapeutic, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Crohn鈥檚 Disease Diagnostic and Therapeutic Breakdown Data by Type
4.1 Global Crohn鈥檚 Disease Diagnostic and Therapeutic Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Crohn鈥檚 Disease Diagnostic and Therapeutic Forecasted 麻豆原创 Size by Type (2025-2030)
5 Crohn鈥檚 Disease Diagnostic and Therapeutic Breakdown Data by Application
5.1 Global Crohn鈥檚 Disease Diagnostic and Therapeutic Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Crohn鈥檚 Disease Diagnostic and Therapeutic Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size (2019-2030)
6.2 North America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Type
6.2.1 North America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Type (2019-2024)
6.2.2 North America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Type (2025-2030)
6.2.3 North America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Share by Type (2019-2030)
6.3 North America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Application
6.3.1 North America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Application (2019-2024)
6.3.2 North America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Application (2025-2030)
6.3.3 North America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Share by Application (2019-2030)
6.4 North America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Country
6.4.1 North America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Country (2019-2024)
6.4.3 North America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size (2019-2030)
7.2 Europe Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Type
7.2.1 Europe Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Type (2019-2024)
7.2.2 Europe Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Type (2025-2030)
7.2.3 Europe Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Share by Type (2019-2030)
7.3 Europe Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Application
7.3.1 Europe Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Application (2019-2024)
7.3.2 Europe Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Application (2025-2030)
7.3.3 Europe Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Share by Application (2019-2030)
7.4 Europe Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Country
7.4.1 Europe Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Country (2019-2024)
7.4.3 Europe Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size (2019-2030)
8.2 China Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Type
8.2.1 China Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Type (2019-2024)
8.2.2 China Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Type (2025-2030)
8.2.3 China Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Share by Type (2019-2030)
8.3 China Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Application
8.3.1 China Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Application (2019-2024)
8.3.2 China Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Application (2025-2030)
8.3.3 China Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size (2019-2030)
9.2 Asia Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Type
9.2.1 Asia Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Type (2019-2024)
9.2.2 Asia Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Type (2025-2030)
9.2.3 Asia Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Share by Type (2019-2030)
9.3 Asia Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Application
9.3.1 Asia Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Application (2019-2024)
9.3.2 Asia Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Application (2025-2030)
9.3.3 Asia Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Share by Application (2019-2030)
9.4 Asia Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Region
9.4.1 Asia Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Region (2019-2024)
9.4.3 Asia Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size (2019-2030)
10.2 Middle East, Africa, and Latin America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Crohn鈥檚 Disease Diagnostic and Therapeutic 麻豆原创 Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Abbvie
11.1.1 Abbvie Company Details
11.1.2 Abbvie Business Overview
11.1.3 Abbvie Crohn鈥檚 Disease Diagnostic and Therapeutic Introduction
11.1.4 Abbvie Revenue in Crohn鈥檚 Disease Diagnostic and Therapeutic Business (2019-2024)
11.1.5 Abbvie Recent Developments
11.2 Celgene
11.2.1 Celgene Company Details
11.2.2 Celgene Business Overview
11.2.3 Celgene Crohn鈥檚 Disease Diagnostic and Therapeutic Introduction
11.2.4 Celgene Revenue in Crohn鈥檚 Disease Diagnostic and Therapeutic Business (2019-2024)
11.2.5 Celgene Recent Developments
11.3 Genetech
11.3.1 Genetech Company Details
11.3.2 Genetech Business Overview
11.3.3 Genetech Crohn鈥檚 Disease Diagnostic and Therapeutic Introduction
11.3.4 Genetech Revenue in Crohn鈥檚 Disease Diagnostic and Therapeutic Business (2019-2024)
11.3.5 Genetech Recent Developments
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Details
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Crohn鈥檚 Disease Diagnostic and Therapeutic Introduction
11.4.4 Johnson & Johnson Revenue in Crohn鈥檚 Disease Diagnostic and Therapeutic Business (2019-2024)
11.4.5 Johnson & Johnson Recent Developments
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Crohn鈥檚 Disease Diagnostic and Therapeutic Introduction
11.5.4 Pfizer Revenue in Crohn鈥檚 Disease Diagnostic and Therapeutic Business (2019-2024)
11.5.5 Pfizer Recent Developments
11.6 Prometheus Laboratories
11.6.1 Prometheus Laboratories Company Details
11.6.2 Prometheus Laboratories Business Overview
11.6.3 Prometheus Laboratories Crohn鈥檚 Disease Diagnostic and Therapeutic Introduction
11.6.4 Prometheus Laboratories Revenue in Crohn鈥檚 Disease Diagnostic and Therapeutic Business (2019-2024)
11.6.5 Prometheus Laboratories Recent Developments
11.7 Salix Pharmaceuticals
11.7.1 Salix Pharmaceuticals Company Details
11.7.2 Salix Pharmaceuticals Business Overview
11.7.3 Salix Pharmaceuticals Crohn鈥檚 Disease Diagnostic and Therapeutic Introduction
11.7.4 Salix Pharmaceuticals Revenue in Crohn鈥檚 Disease Diagnostic and Therapeutic Business (2019-2024)
11.7.5 Salix Pharmaceuticals Recent Developments
11.8 Takeda Pharmaceutical
11.8.1 Takeda Pharmaceutical Company Details
11.8.2 Takeda Pharmaceutical Business Overview
11.8.3 Takeda Pharmaceutical Crohn鈥檚 Disease Diagnostic and Therapeutic Introduction
11.8.4 Takeda Pharmaceutical Revenue in Crohn鈥檚 Disease Diagnostic and Therapeutic Business (2019-2024)
11.8.5 Takeda Pharmaceutical Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Abbvie
Celgene
Genetech
Johnson & Johnson
Pfizer
Prometheus Laboratories
Salix Pharmaceuticals
Takeda Pharmaceutical
听
听
*If Applicable.
